| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Massimo Scacchi, Francesco Cavagnin. Acromegaly. Pituitary. vol 9. issue 4. 2009-06-11. PMID:17077948. |
acromegaly is defined as controlled when, in the absence of clinical activity, igf-i levels are in the age- and sex-matched normal range and gh is normally suppressible by the oral glucose load. |
2009-06-11 |
2023-08-12 |
Not clear |
| Johan A Verhelst, Pascale J Abrams, Roger Ab. Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary. vol 11. issue 1. 2009-06-11. PMID:17530416. |
a 32-year-old woman with mild acromegaly (igf-i: 423 microg/l, gh after ogtt: 2.5 microg/l, adenoma 4 mm) was treated with cabergoline as primary therapy and reached safe gh levels (2 microg/l or less) and normal igf-i levels with 3.5 mg cabergoline weekly. |
2009-06-11 |
2023-08-12 |
Not clear |
| Johan A Verhelst, Pascale J Abrams, Roger Ab. Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary. vol 11. issue 1. 2009-06-11. PMID:17530416. |
a 53-year-old man with moderate acromegaly (serum igf-i: 547 microg/l, gh after ogtt: 5.9 microg/l, adenoma 7 mm) preferred cabergoline as primary therapy. |
2009-06-11 |
2023-08-12 |
Not clear |
| Laurence Katznelso. Alterations in body composition in acromegaly. Pituitary. vol 12. issue 2. 2009-06-04. PMID:18369725. |
acromegaly is a condition characterized by growth hormone (gh) and insulin-like growth factor-1 (igf-1) hypersecretion, and is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions of gh. |
2009-06-04 |
2023-08-12 |
human |
| Laurence Katznelso. Alterations in body composition in acromegaly. Pituitary. vol 12. issue 2. 2009-06-04. PMID:18369725. |
bmd is generally increased in acromegaly, though the anabolic effect of gh excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment. |
2009-06-04 |
2023-08-12 |
human |
| Junko Goto, Fumio Otsuka, Kenichi Inagaki, Naoko Tsukamoto, Jiro Suzuki, Tomoko Miyoshi, Toshio Ogura, Yasuhiko Kamada, Hirofumi Makin. Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. Endocrine journal. vol 56. issue 1. 2009-04-21. PMID:18840925. |
we report a rare case of polycystic ovary syndrome (pcos) complicated with acromegaly due to a growth hormone (gh)-producing pituitary adenoma. |
2009-04-21 |
2023-08-12 |
Not clear |
| Martin Bidlingmaie. Pitfalls of insulin-like growth factor I assays. Hormone research. vol 71 Suppl 1. 2009-04-16. PMID:19153502. |
specifically, igf-i measured by immunoassay is used to diagnose gh deficiency and acromegaly, and to monitor treatment efficacy in patients with acromegaly, particularly those treated with the gh receptor antagonist pegvisomant, as measurement of circulating gh is no longer suitable for monitoring disease activity. |
2009-04-16 |
2023-08-12 |
Not clear |
| S Grottoli, V Gasco, A Mainolfi, G Beccuti, G Corneli, G Aimaretti, C Dieguez, F Casanueva, E Ghig. Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly. Journal of endocrinological investigation. vol 31. issue 12. 2009-04-15. PMID:19246978. |
we aimed to clarify the gh/igf-i and metabolic response to short-term fasting in a gh hypersecretory state such as acromegaly. |
2009-04-15 |
2023-08-12 |
human |
| S Grottoli, V Gasco, A Mainolfi, G Beccuti, G Corneli, G Aimaretti, C Dieguez, F Casanueva, E Ghig. Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly. Journal of endocrinological investigation. vol 31. issue 12. 2009-04-15. PMID:19246978. |
the lack of any gh response to fasting in acromegaly would likely reflect neuroendocrine alterations secondary to the gh hypersecretory state. |
2009-04-15 |
2023-08-12 |
human |
| M van Hoek, L J Hofland, Y B de Rijke, F H van Nederveen, R R de Krijger, P M van Koetsveld, S W J Lamberts, A J van der Lely, W W de Herder, R A Feelder. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. The Journal of clinical endocrinology and metabolism. vol 94. issue 2. 2009-03-30. PMID:19017754. |
a 56-yr-old woman presented with acromegaly, a pulmonary mass, and elevated levels of ghrh, gh, and igf-i. |
2009-03-30 |
2023-08-12 |
Not clear |
| John D Carmichael, Vivien S Bonert, James M Mirocha, Shlomo Melme. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 94. issue 2. 2009-03-30. PMID:19033371. |
gh suppression after oral glucose load [oral glucose tolerance test (ogtt)] and normal age- and gender-matched igf-i levels reflect biochemical control of acromegaly. |
2009-03-30 |
2023-08-12 |
Not clear |
| Julia Szendroedi, Elisabeth Zwettler, Albrecht Ingo Schmid, Marek Chmelik, Giovanni Pacini, Gertrud Kacerovsky, Gerhard Smekal, Peter Nowotny, Oswald Wagner, Christoph Schnack, Guntram Schernthaner, Klaus Klaushofer, Michael Rode. Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly. PloS one. vol 3. issue 12. 2009-02-23. PMID:19093000. |
as growth hormone (gh) excess can reduce insulin sensitivity, we examined the impact of previous acromegaly (am) on glucose metabolism, lipid storage and muscular atp turnover. |
2009-02-23 |
2023-08-12 |
Not clear |
| G Mazziotti, S Bonadonna, M Doga, I Patelli, C Gazzaruso, S B Solerte, E De Menis, A Giustin. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test. Neuroendocrinology. vol 88. issue 4. 2009-02-19. PMID:18617732. |
galanin has previously been demonstrated to induce paradoxical inhibition of growth hormone (gh) secretion in most patients with active acromegaly. |
2009-02-19 |
2023-08-12 |
Not clear |
| G Mazziotti, S Bonadonna, M Doga, I Patelli, C Gazzaruso, S B Solerte, E De Menis, A Giustin. Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test. Neuroendocrinology. vol 88. issue 4. 2009-02-19. PMID:18617732. |
in this study, we assessed gh response to galanin infusion in a series of 17 consecutive patients with active acromegaly, 7 of whom had coexistent type 2 diabetes mellitus and 10 were without either diabetes mellitus or impaired tolerance to glucose. |
2009-02-19 |
2023-08-12 |
Not clear |
| Philippe Chanso. [Acromegaly]. Presse medicale (Paris, France : 1983). vol 38. issue 1. 2009-02-10. PMID:19004612. |
acromegaly is a rare disease usually caused by growth hormone (gh) hypersecretion, due to a pituitary adenoma; in very rare cases, acromegaly is due to ectopic secretion of ghrh, responsible for pituitary hyperplasia. |
2009-02-10 |
2023-08-12 |
Not clear |
| Philippe Chanso. [Acromegaly]. Presse medicale (Paris, France : 1983). vol 38. issue 1. 2009-02-10. PMID:19004612. |
if the lowest gh value (nadir) during ogtt remains above 1microg/l (3miu/l), acromegaly is confirmed. |
2009-02-10 |
2023-08-12 |
Not clear |
| Zenei Arihara, Kanako Sakurai, Shozo Yamada, Osamu Murakami, Kazuhiro Takahash. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus. The Tohoku journal of experimental medicine. vol 216. issue 4. 2009-02-03. PMID:19060447. |
acromegaly is characterized by the somatic disfigurement and excessive production of growth hormone (gh) and insulin-like growth factor-1 (igf-1). |
2009-02-03 |
2023-08-12 |
Not clear |
| Haruna Sakai, Kyoichiro Tsuchiya, Chisato Nakayama, Fumiko Iwashima, Hajime Izumiyama, Masaru Doi, Takanobu Yoshimoto, Motohiro Tsujino, Shozo Yamada, Yukio Hirat. Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocrine journal. vol 55. issue 5. 2009-01-21. PMID:18506091. |
in conclusion, it is suggested that endothelial dysfunction associated with active acromegaly improves soon after tss, which is related to ldl-c and/or insulin resistance, but not to excess gh and/or igf-1 itself. |
2009-01-21 |
2023-08-12 |
human |
| Martin Bidlingmaie. Problems with GH assays and strategies toward standardization. European journal of endocrinology. vol 159 Suppl 1. 2009-01-21. PMID:18819944. |
disorders affecting gh secretion--either gh deficiency or gh excess (acromegaly)--are biochemically defined through peak or nadir concentrations of human gh in response to dynamic tests. |
2009-01-21 |
2023-08-12 |
human |
| Fausto Bogazzi, Dania Russo, Francesco Raggi, Federica Ultimieri, Claudio Urbani, Maurizio Gasperi, Luigi Bartalena, Enio Martin. Transgenic mice overexpressing growth hormone (GH) have reduced or increased cardiac apoptosis through activation of multiple GH-dependent or -independent cell death pathways. Endocrinology. vol 149. issue 11. 2009-01-06. PMID:18617616. |
gh has antiapoptotic effects in cardiac or noncardiac cell lines; however, increased apoptosis has been found in myocardial samples of patients with acromegaly. |
2009-01-06 |
2023-08-12 |
mouse |